SRStuart Richer

Stuart Richer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stuart Richer has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reply to Green-Gomez et al. Comment on “Richer et al. Night Vision and Carotenoids (NVC): A Randomized Placebo Controlled Clinical Trial on Effects of Carotenoid Supplementation on Night Vision in Older Adults. Nutrients 2021, 13, 3191”

    by Stuart Richer, Steven Novil, Taylor Gullett, Avni Dervishi, Sherwin Nassiri, Co Duong, Robert Davis, Pinakin Gunvant Davey

    We welcome the additional reviews and insights of Green-Gomez, Roche and Nolan

  • Open Access

    Night Vision and Carotenoids (NVC): A Randomized Placebo Controlled Clinical Trial on Effects of Carotenoid Supplementation on Night Vision in Older Adults

    by Stuart Richer, Steven Novil, Taylor Gullett, Avni Dervishi, Sherwin Nassiri, Co Duong, Robert Davis, Pinakin Gunvant Davey

    Twilight and low luminance levels are visually challenging environments for the elderly, especially when driving at night. Carotenoid rich diets are known to increase macular pigment optical density (MPOD), which in turn leads to an improvement in visual function. It is not known whether augmenting MPOD can lead to a decrease in vision related night driving difficulties. Additionally, it is unknown if carotenoid supplementation provides additional measurable benefits to one’s useful field of view (UFOV) along with a decreased composite crash risk score. The aim of the study was to evaluate changes in night vision function and UFOV in individuals that took carotenoid vitamin supplements for a six-month period compared to a placebo group. Methods: A prospective, randomized, double-blind, six-month trial of a 14 mg zeaxanthin/7 mg lutein-based supplement was carried out. Participants were randomized into active or placebo group (approx 2:1). Results: n = 33 participants (26 males/7 females) participated with 93% capsule intake compliance in the supplemented group (n = 24) and placebo group (n = 9). MPOD (mean/standard error SE) in the active group increased in the Right eye from 0.35 density units (du)/0.04 SE to 0.41 du/0.05 SE; p < 0.001 and in the Left eye from 0.35 du/0.05 SE to 0.37 du, p > 0.05). The supplemented group showed significant improvements in contrast sensitivity with glare in both eyes with improvements in LogMAR scores of 0.147 and 0.149, respectively (p = 0.02 and 0.01, respectively), monocularly tested glare recovery time improved 2.76 and 2.54 s, respectively, (p = 0.008 and p = 0.02), and we also noted a decreased preferred luminance required to complete visual tasks (p = 0.02 and 0.03). Improvements in UFOV scores of divided attention (p < 0.001) and improved composite crash risk score (p = 0.004) were seen in the supplemented group. The placebo group remained unchanged. Conclusions: The NVC demonstrates that augmenting MPOD in individuals with difficulty in night vision showed measurable benefits in numerous visual functions that are important for night vision driving in this small sample RCT. Additionally, we observed an improvement in UFOV divided attention test scores and decreased composite risk scores.


  • Of Vanishing Retinal Drusen and Oxysterols

    by Stuart Richer, Sherwin Nassiri, Avni Dervishi, Harsh Patel, Anish Bhandari, William Stiles

    Aim: Spontaneous resolution of retinal drusen is a common occurrence in ophthalmology, but little is understood about the mechanistic pathophysiology of this phenomenon. Small molecules, taken orally, such as resveratrol (RV) and zeaxanthin (Z), resolve retinal drusen and amyloid protein, yet few clinicians are aware of this molecular, biochemical progress against the major degenerative disease(s) of ageing. Published Data: We highlight the mechanistic role of resveratrol (RV) in the cytochrome P450 enzymatic pathways of liver detoxification, as well as dosing considerations. RV has demonstrated utility in age-related macular degeneration (AMD) and has application in disorders of cognition (Alzheimer's Disease) and age-related hearing loss. We highlight the clinical evidence for the use of an epigenetic RV nutraceutical matrix called Longevinex®, and the xanthophyll carotenoid zeaxanthin. Longevinex® has been employed against retinal drusen, with resulting normalisation of retinal anatomy, Amsler Grid field loss (scotomas) and distortions of the central visual field (metamorphopsia). Implications: The published evidence for RV and Z resolving structural and functional deficits in AMD is presented. The xanthophyll carotenoid zeaxanthin has now been demonstrated, in a larger population clinical trial, to resolve drusen beyond normal expectation. Both RV and Z have also both shown to induce denser macular pigment, and such small molecules likely play a role in multisensory degeneration(s) of ageing. Conclusion: Previously described “spontaneous resolution” of drusen may have an unappreciated biological mechanism(s). The adjunct and complimentary wound healing benefits of RV and Z remain clinically underutilised in age-related retinal and neuro-degeneration associated diseases of ageing, while the complications of chronic ophthalmologic anti-vascular endothelial growth factor intravitreal injections emerge as problematic.

  • Statins, Caloric Restriction and Longevinex® in a One-eyed Patient with Macular Drusen

    by Anish Bhandari, Mansi Katkar, Stuart Richer, William Stiles

    Aims: Evaluate the effects of Longevinex®, Statins, and caloric restriction in a one-eyed patient with Dominant Drusen. Presentation of Case: A 44-year old male patient with OD congenital amblyopia (20/800 VA) and persistent OS confluent drusen (20/20 VA) (Dominant Drusen) was prescribed AREDS I supplementation for 13 years, with stabile vision and retinal exams. Subsequently, the patient developed worrisome OS Amsler grid distortion along with OS sub-retinal drusenoid deposits (SDD) and retinal architecture disruption. Discussion: A significant increase in the drusen-free macular area (DFMA) of the patient occurred following 2 years of statin drugs and weight reduction and 4 years daily intake of a caloric restriction mimetic nutrient capsule. Only the Longevinex® red wine matrix nutrient complex resulted in complete Amsler grid resolution and sustainable normalisation of his retinal SD-OCT architecture. Conclusion: This case provides a longitudinal perspective on a novel therapy for SDD amelioration with promising results. Within the context of previously published research on Longevinex®, this approach potentially provides an efficient, cost effective, and compassionate strategy for patients at risk for AMD as well.

  • Open Access

    Restoration of Central Macular Pigment Dip with Dietary RR Zeaxanthin Supplementation in Patients with AMD

    by Stuart P Richer

    Objective: Low macular pigment optical density (MPOD) is a major risk factor for agerelated macular degeneration (AMD). This paper investigates the impact of 8 mg dietary RR zeaxanthin (Z) supplementation on MPOD distribution and the associated effect on macular scotomas in patients with a central foveal dip in their macular pigment spatial profile. Methods: This is a retrospective review of The Zeaxanthin and Visual Function RCT (FDA IND 78, 973) with respect to the relation between low levels of MPOD and increased risk of age-related macular degeneration (AMD). We retrospectively examine the effect of daily supplementation of 8 mg of dietary Z on n=4 patients having a baseline central foveal dip in their MPOD distribution. The testing modalities used were a 7⁰ 3D specular reflectance and the associated kinetic 20° macular visual fields. Results: Over a 12-month period, all four patients showed a progressive increase in central peak restoration with related kinetic and/or Amsler grid visual field data. Conclusion: The initial results demonstrate marked improvement in macular pigment architecture and overall visual function after 12 months of Z supplementation. These results warrant a prospective clinical trial with a larger number of subjects to investigate the role of Z in central dip amelioration.


  • Open Access

    Longevinex ® Improves Human Atrophic Aged-related Macular Degeneration (AMD) Photoreceptor / Retinal Pigment Epithelium Mediated Dark Adaptation*

    by Stuart Richer, Lawrence Ulanski-Ii, Anish Bhandari, Natalia Popenko

    Aim: Gradual photoreceptor/ RPE deterioration/ vision loss in AMD is common, irrespective of US NEI AREDS I/II supplement risk reduction, or intra-vitreal anti-VEGF pharmacology. We evaluated dark adaptation (DA), a broad measure of photoreceptor / RPE health, with / without epigenetic modulation using a resveratrol–based caloric-restriction mimic (Longevinex ®www.longevinex.com). Study Design: Case series, bi-ocular, clinical DA evaluation in deteriorating AMD, before and after supplementation, under medical center compassionate use guidelines. Place and Duration of Study: Captain James A Lovell Federal Health Care Center, Illinois, USA, Optometry/Ophthalmology Departments between 4/2015 and 8/2016. Methods: Baseline clinical DA threshold (log DB), time (min), and fixation (%) were taken for patients with established atrophic AMD (n=14 eyes; 6 M / 1 F; ages 64 - 89 years), using the AdaptDx ® (www.maculogix.com), with pupil dilation and best refraction. Following prescription of Longevinex® 1 capsule qd AM, DA was repeated, with each eye’s response considered independent. Results: All but 2 eyes improved in one or more DA parameters, with 3 cases showing improvement by retinal macula SD OCT. Expected vs. actual (worse vs. same/better), by eye, was significant by Chi Square, P < .01. Additional factors affecting DA: smoking, alcohol, elevated CRP and statins were retrospectively evaluated. Conclusion: These first cases of epigenetic-induced DA stability / improvement are consistent with previous beneficial effects of Longevinex® such as enhanced choriocapillaris circulation. DA is the earliest functional AMD sign and a prime candidate for “AMD prevention”. This work merits expansion to controlled studies.

  • The Human Lens: A Living Biometric Indicator of Health Status and Successful Aging

    by Stuart Richer, William Stiles, Pejman Zargar, Mahsa Rezaei, Theresa Vo, Richard Bone, Bill Sardi


  • Open Access

    Resveratrol Based Oral Nutritional Supplement Produces Long-Term Beneficial Effects on Structure and Visual Function in Human Patients

    by Stuart Richer, Shana Patel, Shivani Sockanathan, Lawrence J. Ulanski, Luke Miller, Carla Podella

    Background: Longevinex® (L/RV) is a low dose hormetic over-the-counter (OTC) oral resveratrol (RV) based matrix of red wine solids, vitamin D3 and inositol hexaphosphate (IP6) with established bioavailability, safety, and short-term efficacy against the earliest signs of human atherosclerosis, murine cardiac reperfusion injury, clinical retinal neovascularization, and stem cell survival. We previously reported our short-term findings for dry and wet age-related macular degeneration (AMD) patients. Today we report long term (two to three year) clinical efficacy. Methods: We treated three patients including a patient with an AMD treatment resistant variant (polypoidal retinal vasculature disease). We evaluated two clinical measures of ocular structure (fundus autofluorescent imaging and spectral domain optical coherence extended depth choroidal imaging) and qualitatively appraised changes in macular pigment volume. We further evaluated three clinical measures of visual function (Snellen visual acuity, contrast sensitivity, and glare recovery to a cone photo-stress stimulus). Results: We observed broad bilateral improvements in ocular structure and function over a long time period, opposite to what might be expected due to aging and the natural progression of the patient’s pathophysiology. No side effects were observed. Conclusions: These three cases demonstrate that application of epigenetics has long-term efficacy against AMD retinal disease, when the retinal specialist has exhausted other therapeutic modalities.


  • Open Access

    Observation of Human Retinal Remodeling in Octogenarians with a Resveratrol Based Nutritional Supplement

    by Stuart Richer, William Stiles, Lawrence Ulanski, Donn Carroll, Carla Podella

    Purpose: Rare spontaneous remissions from age-related macular degeneration (AMD) suggest the human retina has large regenerative capacity, even in advanced age. We present examples of robust improvement of retinal structure and function using an OTC oral resveratrol (RV) based nutritional supplement called Longevinex® or L/RV (circa 2004, Resveratrol Partners, LLC, Las Vegas, NV, USA). RV, a polyphenolic phytoalexin caloric-restriction mimic, induces hormesis at low doses with widespread beneficial effects on systemic health. RV alone inhibits neovascularization in the murine retina. Thus far, published evidence includes L/RV mitigation of experimentally induced murine cardiovascular reperfusion injury, amelioration of human atherosclerosis serum biomarkers in a human Japanese randomized placebo controlled trial, modulation of micro RNA 20b and 539 that control hypoxia-inducing-factor (HIF-1) and vascular endothelial growth factor (VEGF) genes in the murine heart (RV inhibited micro RNA20b 189-fold, L/RV 1366-fold). Little is known about the effects of L/RV on human ocular pathology. Methods: Absent FDA IRB approval, but with permission from our Chief of Staff and medical center IRB, L/RV is reserved for AMD patients, on a case-by-case compassionate care basis. Patients include those who progress on AREDS II type supplements, refuse intra-vitreal anti-VEGF injections or fail to respond to Lucentis®, Avastin® or Eylea®. Patients are clinically followed traditionally as well as with multi-spectral retinal imaging, visual acuity, contrast sensitivity, cone glare recovery and macular visual fields. Three cases are presented. Results: Observed dramatic short-term anti-VEGF type effect including anatomic restoration of retinal structure with a suggestion of improvement in choroidal blood flow by near IR multispectral imaging. The visual function improvement mirrors the effect seen anatomically. The effect is bilateral with the added benefit of better RPE function. Effects have lasted for one year or longer when taken daily, at which point one patient required initiation of anti-VEGF agents. Unanticipated systemic benefits were observed. Conclusions: Preliminary observations support previous publications in animals and humans. Restoration of structure and visual function in octogenarians with daily oral consumption of L/RV is documented. Applications include failure on AREDS II supplements, refusing or failing conventional anti-VEGF therapy, adjunct therapy to improve RPE function, and compassionate use in medically underserved or economically depressed third-world countries.


  • Open Access

    Retinal Spectral Domain Optical Coherence Tomography in Early Atrophic Age-Related Macular Degeneration (AMD) and a New Metric for Objective Evaluation of the Efficacy of Ocular Nutrition

    by Stuart Richer, Jane Cho, William Stiles, Marc Levin, James S. Wrobel, Michael Sinai, Carla Thomas

    Purpose: A challenge in ocular preventive medicine is identification of patients with early pathological retinal damage that might benefit from nutritional intervention. The purpose of this study is to evaluate retinal thinning (RT) in early atrophic age-related macular degeneration (AMD) against visual function data from the Zeaxanthin and Visual Function (ZVF) randomized double masked placebo controlled clinical trial (FDA IND #78973). Methods: Retrospective, observational case series of medical center veterans with minimal visible AMD retinopathy (AREDS Report #18 simplified grading 1.4/4.0 bilateral retinopathy). Foveal and extra-foveal four quadrant SDOCT RT measurements were evaluated in n = 54 clinical and ZVF AMD patients. RT by age was determined and compared to the OptoVue SD OCT normative database. RT by quadrant in a subset of n = 29 ZVF patients was correlated with contrast sensitivity and parafoveal blue cone increment thresholds. Results: Foveal RT in AMD patients and non-AMD patients was preserved with age. Extrafoveal regions, however, showed significant slope differences between AMD patients and non-AMD patients, with the superior and nasal quadrants most vulnerable to retinal thinning (sup quad: −5.5 μm/decade thinning vs. Non-AMD: −1.1 μm/decade, P < 0.02; nasal quad: −5.0 μm/decade thinning vs. Non-AMD: −1.0 μm/decade, P < 0.04). Two measures of extrafoveal visual deterioration were correlated: A significant inverse correlation between % RT and contrast sensitivity (r = −0.33, P = 0.01, 2 Tailed Paired T) and an elevated extrafoveal increment blue cone threshold (r = +0.34, P = 0.01, 2 Tailed T). Additional SD OCT RT data for the non-AMD oldest age group (ages 82–91) is needed to fully substantiate the model. Conclusion: A simple new SD OCT clinical metric called “% extra-foveal RT” correlates well with functional visual loss in early AMD patients having minimal visible retinopathy. This metric can be used to follow the effect of repleting ocular nutrients, such as zinc, antioxidants, carotenoids, n-3 essential fats, resveratrol and vitamin D.